健康之路(02587.HK) 8月8日晚间发布公告，根据董事会对本集团截至 2025 年 6 月 30 日止六个月的未 经审核综合管理账目的初步审阅及董事会目前可得资料，本集团预计将于截至 2025 年 6 月 30 日止六个 月录得不少于人民币 600 万元的溢利，而截至 2024 年 6 月 30 日止六个月则录得约人民币 5728 万元的 亏损， 二、价值医疗服务收入减少，主要由于本公司药品批发业务的若干销售代理协议于 2025 年届满，而本 公司正就新销售代理协议进行磋商，以及由于本公司主动调整服务结构及分类，健康医疗综合服务包的 收入减少； 三、数字营销服务收入减少，主要由于经济下滑，导致部分客户选择减少广告及营销开支。 有关本集团截至2025年6月30日止六个月之财务资料的详情，将于本公司截2025年 6 月 30 日止六个月之 中期业绩公告中披露，该公告预计于2025年8月下旬刊发。 据了解，健康之路股份有限公司是国经营数字健康医疗服务平台。 尽管出现上述增长，本集团预计截至 2025 年 6 月 30 日止六个月的收入与 2024 年同期相比将录得约 15% 至 18% 的减少，而截至 202 ...

Group 1 - The company expects to record a profit of no less than RMB 6 million for the six months ending June 30, 2025, compared to a loss of approximately RMB 57.28 million for the same period in 2024 [1] - The anticipated loss in 2024 is primarily due to changes in the redemption liability value from the termination of the priority rights of convertible redeemable preferred shares and expenses incurred during the listing preparation [1] - Despite the expected profit, the company forecasts a revenue decrease of approximately 15% to 18% for the six months ending June 30, 2025, compared to the same period in 2024 [1] Group 2 - The board believes the expected decrease in revenue and gross profit is mainly due to a reduction in content service revenue, as some clients have shifted to direct marketing strategies, reducing reliance on Real World Evidence (RWS) support services [2] - Increased competition in the generic drug industry has led to a shift of resources towards commercialization, resulting in budget cuts for RWS services from some clients [2] - The decline in value-added medical services revenue is attributed to the expiration of several sales agency agreements in 2025 and ongoing negotiations for new agreements, along with a proactive adjustment in service structure and classification [2] - A decrease in digital marketing service revenue is primarily due to the economic downturn, prompting some clients to reduce advertising and marketing expenditures [2]